

Engagement Report for Specialised Commissioning Policies

Unique Reference Number and NICE ID	1693
Policy Title	Long term left ventricular assist device therapy for advanced heart failure (all ages)
Accountable Commissioner	Sarah Watson
Clinical Lead	Mr Steven Tsui
Clinical Reference Group	Cardiac Services
Which stakeholders were contacted to be involved in policy development?	Cardiac Services CRG and registered stakeholders
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Na
Which stakeholders have actually been involved?	Some registered stakeholders, the PWG included a PPV member from the Cardiac Services CRG and a LVAD patient
Explain reason if there is any difference from previous question	Organisations declined the offer to participate in the development of the policy
Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?	Na
How have stakeholders been involved? What engagement	Policy working group meeting and subsequent contact for policy development. Stakeholder engagement process. 14 day email

methods have been used?	engagement exercise with registered stakeholders
What has happened or changed as a result of their input?	<p>One submission was made to the stakeholder consultation Comments have been reviewed by policy working group; no amendments were made to the wording of the draft policy proposition, however it was agreed that a 2 month public consultation be completed to allow time to further discussion with stakeholders during the consultation period.</p> <ol style="list-style-type: none"> 1. It was suggested that up to a 12 week consultation period be agreed to include proactive engagement activities. 2. A suggestion was made that the policy title be changed to reflect the familiar term of destination VADs to limit confusion to the NHS England commissioned VAD service. The PWG felt that the indications included here were clearly not including patients currently eligible for VAD implantation. 3. The respondent commented that there was some contradiction to the NICE IPG 516 on this topic, particularly in relation to current evidence on the efficacy and safety. A NICE IPG does not constitute a recommendation that the treatment should be used, rather than an indication of the circumstances in which it may be used. All investment proposals considered by NHS England require prioritisation against other investment proposals within specialised services and further details of the decision making process for new investment can be found on NHS England's website. The policy presented by NHS England reflects the evidence review commissioned for this work. 4. Further dialogue was requested to further access for patients to LVADs for advanced heart failure. This was noted but is outside of the scope of the PWG. NHS England has agreed a research project on cost effectiveness with the NIHR to further develop the knowledge base and understanding of costs for use of VADs in advanced heart failure. This project should report in 2020.
How are stakeholders being kept informed of progress with policy development as a result of their input?	Stakeholders will be kept informed of the policy's progress through NHS England's consultation portal website.
What level of wider public consultation is recommended by the CRG	The one stakeholder that commented made a recommendation that up to 12 weeks consultation was needed to include some additional proactive engagement

for the NPOC Board to agree as a result of stakeholder involvement?

activities during the live consultation period. It has been agreed therefore that a two month consultation should take place for this draft proposition. It was noted however that the level of stakeholder interest shown during the two week consultation was limited.

Draft for consultation

Draft for consultation